# Dasatinib in Resectable Malignant Pleural Mesothelioma

> **NCT00652574** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 56 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00652574
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-12
- **Primary completion:** 2022-10-07
- **Final completion:** 2022-10-07
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2022-10-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00652574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00652574, "Dasatinib in Resectable Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00652574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*